Phospholipase A2 Regulates Eicosanoid Class Switching During Inflammasome Activation

Total Page:16

File Type:pdf, Size:1020Kb

Phospholipase A2 Regulates Eicosanoid Class Switching During Inflammasome Activation Phospholipase A2 regulates eicosanoid class switching during inflammasome activation Paul C. Norrisa, David Gosselinb, Donna Reichartb, Christopher K. Glassb, and Edward A. Dennisa,1 Departments of aChemistry/Biochemistry and Pharmacology, and bCellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093 Edited by Michael A. Marletta, The Scripps Research Institute, La Jolla, CA, and approved July 30, 2014 (received for review March 13, 2014) Initiation and resolution of inflammation are considered to be to initiate pathogenic killing, subsequent “class switching” to lipoxin tightly connected processes. Lipoxins (LX) are proresolution lipid (LX) formation by “reprogrammed” neutrophils inhibits additional mediators that inhibit phlogistic neutrophil recruitment and pro- neutrophil recruitment during self-resolving inflammatory resolu- mote wound-healing macrophage recruitment in humans via tion (9). The direct link between inflammatory commitment and potent and specific signaling through the LXA4 receptor (ALX). resolution mediated by eicosanoid signaling in macrophages One model of lipoxin biosynthesis involves sequential metabolism remains unclear from short-term vs. long-term priming, but the of arachidonic acid by two cell types expressing a combined trans- complete temporal changes and important interconnections cellular metabolon. It is currently unclear how lipoxins are effi- within the entire eicosadome are now demonstrated. ciently formed from precursors or if they are directly generated after receptor-mediated inflammatory commitment. Here, we pro- Results vide evidence for a pathway by which lipoxins are generated in We first primed immortalized macrophage-like cells (RAW264.7) macrophages as a consequence of sequential activation of toll-like with the TLR4 agonist Kdo2 lipid A (KLA) for various times and receptor 4 (TLR4), a receptor for endotoxin, and P2X7, a purinergic examined the effects on subsequent purinergic stimulated COX receptor for extracellular ATP. Initial activation of TLR4 results in and 5-LOX activity using targeted lipidomic monitoring (Fig. 1A). – accumulation of the cyclooxygenase-2 derived lipoxin precursor Total 5-LOX products (5-HETE, LTC4, 11-trans LTC4,LTB4, 15-hydroxyeicosatetraenoic acid (15-HETE) in esterified form 6-trans,12-epi LTB4, 6-trans LTB4, and 12-epi LTB4) peaked at within membrane phospholipids, which can be enhanced by aspi- 2 h and diminished steadily at later time points; total levels from BIOCHEMISTRY rin (ASA) treatment. Subsequent activation of P2X7 results in effi- 12 to 24 h were less than 1% of maximal 2-h levels. Total COX cient hydrolysis of 15-HETE from membrane phospholipids by products [PGD2, PGE2, PGF2α, PGJ2, 15-deoxy PGD2, 15-deoxy group IVA cytosolic phospholipase A , and its conversion to bio- 2 PGJ2, 11-hydroxyeicosatetraenoic acid (11-HETE) and 15- active lipoxins by 5-lipoxygenase. Our results demonstrate how HETE] were lowest during short-term TLR4 priming and a single immune cell can store a proresolving lipid precursor and then steadily increased with longer priming durations. AA levels in release it for bioactive maturation and secretion, conceptually similar media were maximal with 2-h priming and were vastly reduced to the production and inflammasome-dependent maturation of the with 8-h priming and beyond (Fig. S1); AA release during major proinflammatory IL-1 family cytokines. These findings provide evi- COX activity from 2 to 12 h may therefore be slower and/or dence for receptor-specific and combinatorial control of pro- and coupled to COX-2. anti-inflammatory eicosanoid biosynthesis, and potential avenues The proresolution mediators lipoxin A4 (LXA4) and 15-epi– to modulate inflammatory indices without inhibiting downstream LXA4 were also detected between 4 and 10 h of TLR4 priming eicosanoid pathways. and peaked at 8 h (Fig. 1A). LXA4 and 15-epi–LXA4 are trihy- droxylated eicosanoids derived from 15(S)-HETE and 15(R)- lipidomics | enzyme coupling | membrane remodeling HETE, respectively. The 15-HETE comprises ∼1–3% COX-2 complex network of danger-sensing receptors and bioactive Significance Apeptide and lipid signals, including cytokines and eicosa- noids, regulates innate immunity. Toll-like receptor (TLR) Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is widely priming is suggested as a precautionary step in building a signif- viewed as the primary enzyme responsible for inflammatory icant inflammatory response by driving production of IL-1 family arachidonic acid (AA) release and with high specificity. Our protokines, which remain inactive until a second stimulus drives results demonstrate dual, phase-specific release of AA and them to bioactive maturation and secretion (1). The second step 15-hydroxyeicosatetraenoic (15-HETE) acid by GIVA cPLA2 in of this process has been most strongly linked to extracellular primary and immortalized macrophages during a receptor- ATP and specifically to one of its purinergic receptors, P2X7 (2, mediated program required for complete inflammatory com- 3), particularly in macrophages (4). mitment. These dual actions by GIVA cPLA2 were necessary for TLR stimulations also increase prostaglandin synthesis 2+ biosynthesis of proresolving lipoxins, providing a unique, up- by activating cytosolic phospholipase A2 (cPLA2) through a Ca - stream example of an enzyme linked to both the initiation and independent mechanism to release arachidonic acid (AA) from resolution of inflammation. Further, our results demonstrate phospholipids, and by increasing expression of cyclooxygenase-2 a single-cell mechanism of lipoxin synthesis that is more effi- (COX-2) and microsomal prostaglandin E2 synthase-1. P2X7 stim- cient than the established transcellular biosynthetic mechanisms, 2+ ulation activates cPLA2 through a Ca -dependent mechanism that underscoring the importance of enzyme coupling and the possi- couples AA metabolism with 5-lipoxygenase (5-LOX)-activating + bility of proresolution therapies at the membrane level. protein (FLAP), Ca2 -activated 5-LOX, and constitutive COX-1 to form leukotrienes (LTs) and prostaglandins (PGs). Short-term Author contributions: P.C.N. and E.A.D. designed research; P.C.N., D.G., and D.R. performed 2+ (∼1 h) TLR priming of Ca ionophore/P2X7-activated immune research; P.C.N. and D.R. analyzed data; and P.C.N., C.K.G., and E.A.D. wrote the paper. cells enhances LT synthesis (5, 6), but long-term TLR priming The authors declare no conflict of interest. (16–18 h) significantly suppresses LT synthesis by different cell- This article is a PNAS Direct Submission. type–specific mechanisms (7, 8). 1To whom correspondence should be addressed. Email: [email protected]. Whereas PGE2, PGI2, and LTC4 promote local edema from This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. postcapillary venules, and LTB4 amplifies neutrophil recruitment 1073/pnas.1404372111/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1404372111 PNAS Early Edition | 1of6 Downloaded by guest on September 30, 2021 A levels of COX-2 after TLR4 stimulation (10). RPMs produced lipoxins with long-term priming (Fig. S4 A and B), and increasing 6000 KLA ATP Quench 0.12 Lipoxins cell density increased the level (and concentration) of PGE2, but this did not limit lipoxin formation or 5-LOX metabolism of AA 4000 Time 0.08 based on levels of LTC4 (Fig. S4 C and D). Thus, RPM and cells) 6 RAW macrophages both retain 5-LOX activity in the presence Total COX of exogenous or endogenous PGE , unlike in dendritic cells (8). 2000 Products 0.04 2 Eicosanoid Ultimately, lipoxins from macrophages likely represent an addi- (pmol/10 TotalTotal 5-LOX5-LOX ProductsProducts tional source of the total that might be found in certain physio- 0 0 logical environments. Lipoxins can be formed by coordinate 02481216 20 402481216 20 4conversion of endothelial COX-2/mucosal epithelial 15-LOX– Duration of TLR4 Priming (Hr) derived 15-HETE with neutrophil 5-LOX, or neutrophil 5-LOX– Total 5-LOX derived LTA with platelet 12-LOX, which inhibit neutrophil B PGD Lipoxins 4 2 Products extravasation (12). Macrophages initially recruit neutrophils via 500 0.25 100 Control leukotriene and chemokine signaling in response to TLR signaling 400 0.20 75 Celecoxib and may subsequently switch to forming lipoxins to inhibit neu- cells) 6 300 0.15 *** trophil recruitment in response to high ATP levels. ** 50 200 *** 0.10 To assess the enzymatic control of lipoxin formation, chiral Eicosanoid chromatography was used to determine the proportions of 15(R)- 100 0.05 25 (pmol/10 * N.D. HETE and 15(S)-HETE in TLR4 primed/purinergic-stimulated 0 0 0 1 7.5 1 7.5 1 7.5 RAW cells in the presence and absence of aspirin (ASA). Acet- ylation of COX-2 by ASA inhibits PG formation and enhances Duration of TLR4 Priming (Hr) 15(R)-HETE formation (13). Non–ASA-treated cells produced Fig. 1. Duration of TLR4 priming controls purinergic 5-LOX product for- 15(R)- and 15(S)-HETE at a ratio between 1:3 and 1:4 (R:S) mation and lipoxin biosynthesis. (A, Inset) Protocol for TLR4 priming (Kdo2 (Fig. 2A),andproducedbothlipoxinepimersataratioof∼1:2 lipid A, KLA) starting at time = 0 followed by ATP stimulation at indicated (15-epi–LXA4:LXA4). In the presence of ASA, RAW cells pro- times and subsequent reaction quench as endpoint (further details can be duced almost exclusively 15(R)-HETE and 15-epi–LXA4. These found in SI Materials and Methods); eicosanoid levels from RAW264.7 (RAW) results demonstrate that COX-2 activity with or without aspirin cell medium after TLR4 priming with 100 ng/mL KLA for varying durations – before stimulation with 2 mM ATP for the final 10 min include total COX treatment can lead to formation of 15-epi LXA4, which is more products (PGD2, PGE2, PGF2α, PGJ2, 15-deoxy PGD2, 15-deoxy PGJ2, 11-HETE, slowly inactivated by 15-hydroxyprostaglandin dehydrogenase and 15-HETE); total 5-LOX products (5-HETE, LTC4, 11-trans LTC4,LTB4, (PGDH) than LXA4 (12). Lipoxins are well known to be formed – 6-trans,12-epi LTB4, 6-trans LTB4, and 12-epi LTB4); lipoxins (LXA4 and 15-epi by either 12- or 15-LOX activity along with 5-LOX, although – LXA4).
Recommended publications
  • Role of 15-Lipoxygenase/15-Hydroxyeicosatetraenoic Acid in Hypoxia-Induced Pulmonary Hypertension
    J Physiol Sci (2012) 62:163–172 DOI 10.1007/s12576-012-0196-9 REVIEW Role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in hypoxia-induced pulmonary hypertension Daling Zhu • Yajuan Ran Received: 29 September 2011 / Accepted: 25 January 2012 / Published online: 14 February 2012 Ó The Physiological Society of Japan and Springer 2012 Abstract Pulmonary arterial hypertension (PAH) is a Introduction rare disease with a complex aetiology characterized by elevated pulmonary artery resistance, which leads to right Pulmonary hypertension (PH) is a severe and frequently heart ventricular afterload and ultimately progressing to fatal disease characterized by elevated mean pulmonary right ventricular failure and often death. In addition to arterial (PA) pressure greater than 25 mmHg at rest or other factors, metabolites of arachidonic acid cascade play greater than 30 mmHg with exercise [1], and which con- an important role in the pulmonary vasculature, and dis- tributes to the morbidity and mortality of adult and pedi- ruption of signaling pathways of arachidonic acid plays a atric patients with various lung and heart diseases. central role in the pathogenesis of PAH. 15-Lipoxygenase According to the Venice Classification of Pulmonary (15-LO) is upregulated in pulmonary artery endothelial Hypertension in 2003, PH is currently classified into five cells and smooth muscle cells of PAH patients, and its categories as listed in Table 1. Importantly, many of these metabolite 15-hydroxyeicosatetraenoic acid (15-HETE) in diseases or conditions are associated with persistent or particular seems to play a central role in the contractile intermittent hypoxia, either globally or regionally, within machinery, and in the initiation and propagation of cell confined areas of the lung [2].
    [Show full text]
  • Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 56, No. 14, 2010 © 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.06.015 QUARTERLY FOCUS ISSUE: PREVENTION/OUTCOMES Clinical Research Early Phase Clinical Trials Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients Robert S. Rosenson, MD,* Colin Hislop, MD,† Michael Elliott, MA,† Yuri Stasiv, PHD,† Michael Goulder, BSC,‡ David Waters, MD§ New York, New York; Hayward and San Francisco, California; Nottingham, United Kingdom Objectives The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary syndrome patients. Background Secretory phospholipase A2 (sPLA2) represents a family of proatherogenic enzymes that hydrolyze lipoprotein phospholipids, increasing their affinity for intimal proteoglycans; contribute to cholesterol loading of macro- phages by nonscavenger receptor mediated pathways; and activate inflammatory pathways. In prospective stud- ies, high sPLA2-IIA levels predicted major adverse cardiovascular events in acute coronary syndrome (ACS) and stable coronary heart disease patients. Methods This randomized, double-blind, prospective controlled clinical trial (phase 2B) was designed to investigate the effects of sPLA2 inhibition with varespladib 500 mg daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on biomarkers (low-density lipoprotein cholesterol [LDL-C], high-sensitivity C-reactive protein [hsCRP], and sPLA2-IIA lev- els), major adverse cardiovascular events (unstable angina, myocardial infarction, death), and safety.
    [Show full text]
  • Epigenetic Regulations of Ahr in the Aspect of Immunomodulation
    International Journal of Molecular Sciences Review Epigenetic Regulations of AhR in the Aspect of Immunomodulation Anna Wajda 1,* , Joanna Łapczuk-Roma ´nska 2 and Agnieszka Paradowska-Gorycka 1 1 Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland; [email protected] 2 Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected] Received: 31 July 2020; Accepted: 28 August 2020; Published: 3 September 2020 Abstract: Environmental factors contribute to autoimmune disease manifestation, and as regarded today, AhR has become an important factor in studies of immunomodulation. Besides immunological aspects, AhR also plays a role in pharmacological, toxicological and many other physiological processes such as adaptive metabolism. In recent years, epigenetic mechanisms have provided new insight into gene regulation and reveal a new contribution to autoimmune disease pathogenesis. DNA methylation, histone modifications, chromatin alterations, microRNA and consequently non-genetic changes in phenotypes connect with environmental factors. Increasing data reveals AhR cross-roads with the most significant in immunology pathways. Although study on epigenetic modulations in autoimmune diseases is still not well understood, therefore future research will help us understand their pathophysiology and help to find new therapeutic strategies. Present literature review
    [Show full text]
  • Environmental Pollution 275 (2021) 116665
    Environmental Pollution 275 (2021) 116665 Contents lists available at ScienceDirect Environmental Pollution journal homepage: www.elsevier.com/locate/envpol Metabolomics reveals the reproductive abnormality in female zebrafish exposed to environmentally relevant levels of climbazole* Ting Zou a, 1, Yan-Qiu Liang b, 1, Xiaoliang Liao a, Xiao-Fan Chen a, Tao Wang c, * Yuanyuan Song c, Zhi-Cheng Lin a, Zenghua Qi a, Zhi-Feng Chen a, d, , Zongwei Cai a, c a Guangdong Key Laboratory of Environmental Catalysis and Health Risk Control, School of Environmental Science and Engineering, Institute of Environmental Health and Pollution Control, Guangdong University of Technology, Guangzhou, 510006, China b Faculty of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang, 524088, China c State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong Special Administrative Region, China d Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety, South China Normal University, Guangzhou, 510006, China article info abstract Article history: Climbazole (CBZ) ubiquitously detected in the aquatic environment may disrupt fish reproductive Received 15 November 2020 function. Thus far, the previous study has focused on its transcriptional impact of steroidogenesis-related Received in revised form genes on zebrafish, but the underlying toxic mechanism still needs further investigation at the metabolic 10 January 2021 level. In this study, adult zebrafish were chronically exposed to CBZ at concentrations of 0.1 (corre- Accepted 2 February 2021 sponding to the real concentration in surface water), 10, and 1000 mg/L and evaluated for reproductive Available online 5 February 2021 function by egg production, with subsequent ovarian tissue samples taken for histology, metabolomics, and other biochemical analysis.
    [Show full text]
  • Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
    International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G.
    [Show full text]
  • Lipoxin A4: a Novel Anti-Inflammatory Molecule? Thorax: First Published As 10.1136/Thx.50.2.111 on 1 February 1995
    Thorax 1995;50:111-112 illl Lipoxin A4: a novel anti-inflammatory molecule? Thorax: first published as 10.1136/thx.50.2.111 on 1 February 1995. Downloaded from Arachidonic acid is metabolised by the cyclooxygenase contractions.22 These studies support the view that LXA4 pathway to the prostaglandins and thromboxane A2 or via may act as a partial agonist at the same or similar site as one of the lipoxygenase pathways.' Three major lip- the sulphidopeptide leukotrienes. oxygenase pathways have been identified in mammalian The fact that 1 5-lipoxygenase is abundant in lung tissue tissue - namely, the 5-, 12-, and 15-lipoxygenases.2A The and that LXA4 has been recovered in the bronchoalveolar 5-lipoxygenase pathway metabolises arachidonic acid lavage fluid ofpatients with asthma and other lung diseases through two intermediates, 5-hydroperoxyeicosatetranoic suggests that LXA4 may be a potential mediator or mod- acid (5-HPETE) and leukotriene A4 (LTA4), to LTB4 and ulator of inflammation in the lung. In a recent study eight the sulphidopeptide leukotrienes LTC4, LTD4, and LTE4.5 subjects underwent inhalation challenge with LXA4,23 but The sulphidopeptide leukotrienes are potent spasmogens6 no effect was seen on specific conductance, rate of airflow for non-vascular smooth muscle and may play a part in at 25% vital capacity (V25), blood pressure, pulse, or the pathogenesis of bronchial asthma.7`10 asthmatic symptoms. There was, however, a significant The interactions between 5-lipoxygenase and 15-lip- shift of the specific conductance and V25 dose-response oxygenase on arachidonic acid metabolism have recently curve to the right after inhalation challenge with LTC4 been studied and a new series of biologically active me- combined with LXA4 compared with that after inhalation tabolites described." 12 These molecules have been termed challenge with LTC4 alone.
    [Show full text]
  • University of California, San Diego
    UNIVERSITY OF CALIFORNIA, SAN DIEGO A Lipidomic Perspective on Inflammatory Macrophage Eicosanoid Signaling A Thesis submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry by Paul Christopher Norris Committee in charge: Professor Edward A. Dennis, Chair Professor Pieter C. Dorrestein Professor Partho Ghosh Professor Christopher K. Glass Professor Michael J. Sailor 2013 The Dissertation of Paul Christopher Norris is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Chair University of California, San Diego 2013 iii DEDICATION To my parents, Darrell and Kathy, for always allowing me to think (and choose) for myself. iv TABLE OF CONTENTS Signature page ............................................................................................................................ iii Dedication .................................................................................................................................. iv Table of contents ......................................................................................................................... v List of symbols and abbreviations ........................................................................................... viii List of figures ............................................................................................................................. xi List of tables ............................................................................................................................
    [Show full text]
  • The Relationship Between Specialized Pro-Resolving Lipid Mediators, Morbid Obesity and Weight Loss After Bariatric Surgery
    www.nature.com/scientificreports OPEN The relationship between specialized pro‑resolving lipid mediators, morbid obesity and weight loss after bariatric surgery Fabian Schulte1,2,7, Abdul Aziz Asbeutah3,6,7, Peter N. Benotti4, G. Craig Wood4, Christopher Still4, Bruce R. Bistrian5, Markus Hardt1,2 & Francine K. Welty3* Obesity and diabetes are associated with chronic infammation. Specialized pro‑resolving lipid mediators (SPMs)—resolvins (Rv), protectins (PD) and maresins (MaR)—actively resolve infammation. Bariatric surgery achieves remission of diabetes, but mechanisms are unclear. We measured SPMs and proinfammatory eicosanoid levels using liquid chromatography‑tandem mass spectrometry in 29 morbidly obese subjects (13 with diabetes) and 15 nondiabetic, mildly obese subjects. Compared to the mildly obese, the morbidly obese had higher levels of SPMs—RvD3, RvD4 and PD1—and white blood cells (WBC) and platelets. Post‑surgery, SPM and platelet levels decreased in morbidly obese nondiabetic subjects but not in diabetic subjects, suggesting continued infammation. Despite similar weight reductions 1 year after surgery (44.6% vs. 46.6%), 8 diabetes remitters had signifcant reductions in WBC and platelet counts whereas fve non‑remitters did not. Remitters had a 58.2% decrease (p = 0.03) in 14‑HDHA, a maresin pathway marker; non‑remitters had an 875.7% increase in 14‑HDHA but a 36.9% decrease in MaR1 to a median of 0. In conclusion, higher levels of RvD3, PD1 and their pathway marker, 17‑HDHA, are markers of leukocyte activation and infammation in morbid obesity and diabetes and diminish with weight loss in nondiabetic but not diabetic subjects, possibly representing sustained infammation in the latter.
    [Show full text]
  • Reduced 15-Lipoxygenase 2 and Lipoxin A4/Leukotriene B4 Ratio in Children with Cystic Fibrosis
    ORIGINAL ARTICLE CYSTIC FIBROSIS Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis Fiona C. Ringholz1, Paul J. Buchanan1, Donna T. Clarke1, Roisin G. Millar1, Michael McDermott2, Barry Linnane1,3,4, Brian J. Harvey5, Paul McNally1,2 and Valerie Urbach1,6 Affiliations: 1National Children’s Research Centre, Crumlin, Dublin, Ireland. 2Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland. 3Midwestern Regional Hospital, Limerick, Ireland. 4Centre for Interventions in Infection, Inflammation and Immunity (4i), Graduate Entry Medical School, University of Limerick, Limerick, Ireland. 5Molecular Medicine Laboratories, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. 6Institut National de la Sante´ et de la Recherche Me´dicale, U845, Faculte´ de Me´decine Paris Descartes, Paris, France. Correspondence: Valerie Urbach, National Children’s Research Centre, Crumlin, Dublin 12, Ireland. E-mail: [email protected] ABSTRACT Airway disease in cystic fibrosis (CF) is characterised by impaired mucociliary clearance, persistent bacterial infection and neutrophilic inflammation. Lipoxin A4 (LXA4) initiates the active resolution of inflammation and promotes airway surface hydration in CF models. 15-Lipoxygenase (LO) plays a central role in the ‘‘class switch’’ of eicosanoid mediator biosynthesis from leukotrienes to lipoxins, initiating the active resolution of inflammation. We hypothesised that defective eicosanoid mediator class switching contributes to the failure to resolve inflammation in CF lung disease. Using bronchoalveolar lavage (BAL) samples from 46 children with CF and 19 paediatric controls we demonstrate that the ratio of LXA4 to leukotriene B4 (LTB4) is depressed in CF BAL (p,0.01), even in the absence of infection (p,0.001).
    [Show full text]
  • Strict Regio-Specificity of Human Epithelial 15-Lipoxygenase-2
    Strict Regio-specificity of Human Epithelial 15-Lipoxygenase-2 Delineates its Transcellular Synthesis Potential Abigail R. Green, Shannon Barbour, Thomas Horn, Jose Carlos, Jevgenij A. Raskatov, Theodore R. Holman* Department Chemistry and Biochemistry, University of California Santa Cruz, 1156 High Street, Santa Cruz CA 95064, USA *Corresponding author: Tel: 831-459-5884. Email: [email protected] FUNDING: This work was supported by the NIH NS081180 and GM56062. Abbreviations: LOX, lipoxygenase; h15-LOX-2, human epithelial 15-lipoxygenase-2; h15-LOX-1, human reticulocyte 15-lipoxygenase-1; sLO-1, soybean lipoxygenase-1; 5-LOX, leukocyte 5-lipoxygenase; 12-LOX, human platelet 12-lipoxygenase; GP, glutathione peroxidase; AA, arachidonic acid; HETE, hydoxy-eicosatetraenoic acid; HPETE, hydroperoxy-eicosatetraenoic acid; diHETEs, dihydroxy-eicosatetraenoic acids; 5-HETE, 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-HPETE, 5-hydro peroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 12-HPETE, 12-hydroperoxy-5Z,8Z,10E, 14Z-eicosatetraenoic acid; 15-HPETE, 15-hydroperoxy-5Z,8Z,10Z,13E- eicosatetraenoic acid; 5,15-HETE, 5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid; 5,15-diHPETE, 5,15-dihydroperoxy-6E,8Z,10Z,13E-eicosatetraenoic acid; 5,6- diHETE, 5S,6R-dihydroxy-7E,9E,11Z,14Z-eicosatetraenoic acid; LTA4, 5S-trans-5,6- oxido-7E,9E,11Z,14Z-eicosatetraenoic acid; LTB4, 5S,12R-dihydroxy-6Z,8E,10E,14Z- eicosatetraenoic acid; LipoxinA4 (LxA4), 5S,6R,15S-trihydroxy-7E,9E,11Z,13E- eicosatetraenoic acid; LipoxinB4 (LxB4), 5S,14R,15S-trihydroxy-6E,8Z,10E,12E- eicosatetraenoic acid. Abstract Lipoxins are an important class of lipid mediators that induce the resolution of inflammation, and arise from transcellular exchange of arachidonic acid (AA)- derived lipoxygenase products.
    [Show full text]
  • Nutrition Bytes
    UCLA Nutrition Bytes Title Theories Presented in The Zone Permalink https://escholarship.org/uc/item/9pg2j7wk Journal Nutrition Bytes, 3(1) ISSN 1548-4327 Author Chang, Jeannie Publication Date 1997 Peer reviewed eScholarship.org Powered by the California Digital Library University of California "Easy -to -follow" diet plans appear each year to convince overweight Americans that there is finally a way to lose weight permanently. Barry Sears and Bill Lawren’s book, The Zone, is no exception; in fact, Sears’ book cover advertises that it is "a dietary road map to lose weight permanently, reset your genetic code, prevent disease, achieve maximum physical performance, [and] enhance mental productivity." But is this realistic? Can a diet really accomplish all of those tasks? After numerous searches through several databases, only two journal articles analyzing this diet plan surfaced, both warning readers about the misinformation contained in the book. There are definitely problems with Sears’ diet; for example, his daily caloric intake recommendation is dangerously low. Tufts University Diet and Nutrition Letter stated that they believed "[Sears was] confusing the near -euphoria he promises from following the Zone diet with lightheadedness from hunger" (3). Dr. Zamenhof, Associate Professor of Biological Ch emistry at UCLA said that it was probably due to an increased release of endorphins, enkephalins, and catecholamines. In addition, the information he provides regarding carbohydrate and fat metabolism, as well as insulin and glucagon secretion, are wrong. However, Sears also says that there is a direct relationship between insulin and glucagon with the synthesis of "good" eicosanoids (prostaglandin E1 and prostaglandin I2 and "bad" eicosanoids (prostaglandin E2, thromboxanes, and leukotrienes).
    [Show full text]
  • A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries
    Cancers 2019 S1 of S18 Supplementary Materials: A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries Danilo Fiore, Luca Vincenzo Cappelli, Paul Zumbo, Jude M. Phillip, Zhaoqi Liu, Shuhua Cheng, Liron Yoffe, Paola Ghione, Federica Di Maggio, Ahmet Dogan, Inna Khodos, Elisa de Stanchina, Joseph Casano, Clarisse Kayembe, Wayne Tam, Doron Betel, Robin Foa’, Leandro Cerchietti, Raul Rabadan, Steven Horwitz, David M. Weinstock and Giorgio Inghirami A B C Figure S1. (A) Histology micrografts on IL89 PDTX show overall similarity between T1 T3 and T7 passages (upper panels). Immunohistochemical stains with the indicated antibodies (anti-CD3, anti- CD25 and anti-CD8 [x20]) (lower panels). (B) Flow cytometry panel comprehensive of the most represented surface T-cell lymphoma markers, including: CD2, CD3, CD4, CD5, CD8, CD16, CD25, CD30, CD56, TCRab, TCRgd. IL89 PDTX passage T3 is here depicted for illustration purposes. (C) Analysis of the TCR gamma specific rearrangement clonality in IL89 diagnostic sample and correspondent PDTX after 1 and 5 passages (T1 and T5). A WT Primary p.G1097D IL89 T1 p.G1097D IL89 T5 p.G1097D IL89 cell line B Figure S2. (A) Sanger sequencing confirms the presence of the JAK1 p.G1097D mutation in IL89 PDTX samples and in the cell line, but the mutation is undetectable in the primary due to the low sensitivity of the technique. (B) Manual backtracking of mutations in the primary tumor using deep sequencing data allowed for the identification of several hits at a very low VAF compared to the PDTX-T5. A B IL89 CTRL 30 CTRL Ruxoli?nib S 20 M Ruxoli?nib A R G 10 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 1 1 1 1 1 WEEKS AFTER ENGRAFTMENT Figure S3.
    [Show full text]